×

Subscribe Today

Get our free articles delivered directly to your email!

Continue reading

Ayala Pharmaceuticals Inc. (AYLA) NASDAQ

$0.50 - (-)

Market Cap: -

As of 01/18/23 12:00 AM EST. Market closed.

(AYLA)

Ayala Pharmaceuticals Inc. (AYLA)
NASDAQ

$0.50
- (-)

Market Cap: -

As of 01/18/23 12:00 AM EST. Market closed.

Add to Portfolio

Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. Ayala's approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted ... read more

Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. Ayala's approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL102, targeting the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma, Triple Negative Breast Cancer (TNBC), T-cell Acute Lymphoblastic Leukemia (T-ALL), Desmoid Tumors and Multiple Myeloma (MM) (in collaboration with Novartis). AL101 has received Fast Track Designation and Orphan Drug Designation from the U.S. FDA and is currently in a Phase 2 clinical trial for patients with ACC (ACCURACY) bearing Notch activating mutations and in a Phase 2 clinical trial for patients with TNBC (TENACITY) bearing Notch activating mutations and other gene rearrangements. AL102 is currently being advanced to a Phase 2/3 clinical trials for patients with desmoid tumors (RINGSIDE). read less

COMPANY PROFILE
Sector
Manufacturing
Industry
Biological Product (except Diagnostic) Manufacturing
URL
Address
.
Sector
Manufacturing
Industry
Biological Product (except Diagnostic) Manufacturing
Full Time Employees
35
Address
.
PRICE CHART FOR AYALA PHARMACEUTICALS INC
1w
1m
3m
6m
YTD
1y
5y
MAX
From: To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
-
Previous Close
$0.50
Days Range
$0.44 - $0.57
52 week range
- - -
Volume
0
Avg. Volume (30 days)
0
Market Cap
-
Dividend Yield
-
P/E
-
Shares Outstanding
14,820,727
Open
-
Previous Close
$0.50
Days Range
$0.44 - $0.57
52 week range
- - -
Volume
0
Avg. Volume (30 days)
0
Market Cap
-
Dividend Yield
-
P/E
-
Shares Outstanding
14,820,727
FINANCIAL STATEMENTS FOR AYALA PHARMACEUTICALS INC
LOADING...

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR AYALA PHARMACEUTICALS INC
OwnerRelationshipDateTransactionCost# SharesValue($)Total SharesForm 4
SIDRANSKY DAVIDDirectorMay 12, 2020 Buy$15.0225376225Mar 08, 2021, 04:15 PM
SIDRANSKY DAVIDDirectorDec 23, 2020 Buy$11.56446250Mar 08, 2021, 04:15 PM
SIDRANSKY DAVIDDirectorMay 08, 2020 Buy$15.272003,054200Mar 08, 2021, 04:15 PM
SIDRANSKY DAVIDDirectorSep 14, 2020 Buy$10.70111246Mar 08, 2021, 04:15 PM
SIDRANSKY DAVIDDirectorSep 11, 2020 Buy$10.0710101245Mar 08, 2021, 04:15 PM
SIDRANSKY DAVIDDirectorAug 14, 2020 Buy$11.07555235Mar 08, 2021, 04:15 PM
SIDRANSKY DAVIDDirectorJul 17, 2020 Buy$11.86447230Mar 08, 2021, 04:15 PM
SIDRANSKY DAVIDDirectorJul 07, 2020 Buy$9.60110226Mar 08, 2021, 04:15 PM
Gordon Gary B.Chief Medical OfficerFeb 24, 2021 Option Exercise$5.163,00015,48011,520Feb 26, 2021, 05:47 PM
Gordon Gary B.Chief Medical OfficerFeb 24, 2021 Sale$17.463,00052,3858,520Feb 26, 2021, 05:47 PM
Mamluk RoniPresident & CEOFeb 22, 2021 Sale$19.8615,200301,813163,271Feb 24, 2021, 05:42 PM
Mamluk RoniPresident & CEOFeb 24, 2021 Sale$17.4010,800187,919145,345Feb 24, 2021, 05:42 PM
Mamluk RoniPresident & CEOFeb 23, 2021 Sale$17.897,126127,483156,145Feb 24, 2021, 05:42 PM
Mamluk RoniPresident & CEOJan 21, 2021 Sale$15.041,40621,147178,471Jan 22, 2021, 04:05 PM
Mamluk RoniPresident & CEOJan 20, 2021 Sale$15.0319,466292,533179,877Jan 22, 2021, 04:05 PM
Gordon Gary B.Chief Medical OfficerJan 20, 2021 Option Exercise$5.163,00015,48011,520Jan 22, 2021, 04:05 PM
Gordon Gary B.Chief Medical OfficerJan 20, 2021 Sale$15.033,00045,0848,520Jan 22, 2021, 04:05 PM
Harel Insurance Co LTD10% OwnerMay 12, 2020 Buy$15.00550,0008,250,0002,163,834May 14, 2020, 08:30 PM
Israel Biotech Fund I, L.P.10% OwnerMay 12, 2020 Buy$15.00225,0003,375,0003,315,119May 14, 2020, 04:41 PM
aMoon 2 Fund Limited Partnership10% OwnerMay 12, 2020 Buy$15.00800,00012,000,0002,991,473May 14, 2020, 04:31 PM
Load More Insider Transactions
Buy Sale Option Exercise
OwnerRelationshipDateValue($)
SIDRANSKY DAVIDDirector05/12/2020376
SIDRANSKY DAVIDDirector12/23/202046
SIDRANSKY DAVIDDirector05/08/20203,054
SIDRANSKY DAVIDDirector09/14/202011
SIDRANSKY DAVIDDirector09/11/2020101
SIDRANSKY DAVIDDirector08/14/202055
SIDRANSKY DAVIDDirector07/17/202047
SIDRANSKY DAVIDDirector07/07/202010
Gordon Gary B.Chief Medical Officer02/24/202115,480
Gordon Gary B.Chief Medical Officer02/24/202152,385
Mamluk RoniPresident & CEO02/22/2021301,813
Mamluk RoniPresident & CEO02/24/2021187,919
Mamluk RoniPresident & CEO02/23/2021127,483
Mamluk RoniPresident & CEO01/21/202121,147
Mamluk RoniPresident & CEO01/20/2021292,533
Gordon Gary B.Chief Medical Officer01/20/202115,480
Gordon Gary B.Chief Medical Officer01/20/202145,084
Harel Insurance Co LTD10% Owner05/12/20208,250,000
Israel Biotech Fund I, L.P.10% Owner05/12/20203,375,000
aMoon 2 Fund Limited Partnership10% Owner05/12/202012,000,000
Load More Insider Transactions
BUYBACK ANNOUNCEMENT(S) FOR AYALA PHARMACEUTICALS INC
LOADING...